STOCK TITAN
  1. Home
  2. Sec-filings
  3. KPTI
  4. [8-K] Karyopharm Therapeutics Inc. Reports Material Event

Karyopharm Therapeutics (NASDAQ: KPTI) grants 2026 cash retention awards to key executives

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. approved a new 2026 Leadership Cash Retention Program on July 13, 2026 for certain employees, including all named executive officers and the Chief Financial Officer. The program is intended to incentivize retention of key employees during a period in which the company is expecting several meaningful catalysts.

The program replaces previously guaranteed amounts under the company’s Annual Bonus Plan for 2026. Lump-sum cash retention awards will be paid as follows: Richard Paulson, President and CEO, $1,725,000; Stuart Poulton, EVP and Chief Development Officer, $640,000; Dr. Reshma Rangwala, EVP, Chief Medical Officer and Head of Research, $725,000; and Lori Macomber, EVP, Chief Financial Officer and Treasurer, $625,000.

Awards may be subject to repayment if employment ends for any reason other than by the company without cause, by the executive for good reason, or due to death or permanent disability, before the earlier of 12 months from the payment date or 30 days after a qualifying corporate event. Amounts paid under this program will reduce payments due under previously agreed severance arrangements.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
CEO cash retention award $1,725,000 Lump-sum award to Richard Paulson under 2026 Leadership Cash Retention Program
Chief Development Officer award $640,000 Lump-sum award to Stuart Poulton under 2026 Leadership Cash Retention Program
Chief Medical Officer award $725,000 Lump-sum award to Dr. Reshma Rangwala under 2026 Leadership Cash Retention Program
Chief Financial Officer award $625,000 Lump-sum award to Lori Macomber under 2026 Leadership Cash Retention Program
Repayment look-back period 12 months Employment termination before 12 months from payment date can trigger repayment
Post-corporate event window 30 days Repayment condition measured up to 30 days after a qualifying corporate event
2026 Leadership Cash Retention Program financial
"implemented a retention program... the "2026 Leadership Cash Retention Program""
good reason regulatory
"by the participant for good reason or due to the participant’s death"
qualifying corporate event financial
"prior to the earlier of (i) 12 months... and (ii) 30 days following a qualifying corporate event"
severance arrangements financial
"will reduce any amounts payable under previously agreed upon severance arrangements"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Karyopharm Therapeutics (KPTI) approve on July 13, 2026?
Karyopharm Therapeutics approved a 2026 Leadership Cash Retention Program for certain employees, including its named executive officers and CFO, to incentivize retention during a period with several expected meaningful catalysts.

How much will each KPTI executive receive under the 2026 Leadership Cash Retention Program?
Under the program, Richard Paulson will receive $1,725,000, Stuart Poulton $640,000, Dr. Reshma Rangwala $725,000, and Lori Macomber $625,000 as lump-sum cash retention awards.

How does the new retention program affect KPTI’s 2026 Annual Bonus Plan?
The 2026 Leadership Cash Retention Program replaces previously guaranteed amounts under Karyopharm’s Annual Bonus Plan for 2026, effectively shifting guaranteed compensation for these executives into retention-focused cash awards.

Under what conditions must KPTI executives repay their 2026 retention awards?
Awards may be subject to repayment if employment terminates for any reason other than company termination without cause, resignation for good reason, or death or permanent disability before the earlier of 12 months from payment or 30 days after a qualifying corporate event.

How do KPTI’s 2026 retention payments interact with existing severance arrangements?
Amounts paid under the 2026 Leadership Cash Retention Program will reduce any amounts otherwise payable under previously agreed severance arrangements, preventing executives from receiving both full retention and full severance on overlapping compensation.

Which KPTI executives are covered by the 2026 Leadership Cash Retention Program?
Covered participants include named executive officers and the Chief Financial Officer: Richard Paulson, Stuart Poulton, Dr. Reshma Rangwala, and Lori Macomber, each receiving a specified lump-sum cash retention award.
false 0001503802 0001503802 2026-07-13 2026-07-13
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 13, 2026

 

 

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-36167   26-3931704

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

85 Wells Avenue, 2nd Floor

Newton, Massachusetts

   02459
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   KPTI   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 13, 2026, the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), upon recommendation of its Compensation Committee, implemented a retention program for certain employees of the Company, including each of the Company’s named executive officers and the Chief Financial Officer (the “2026 Leadership Cash Retention Program”). The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees. The 2026 Leadership Cash Retention Program replaces previously guaranteed amounts under the Company’s Annual Bonus Plan for 2026. Under the 2026 Leadership Cash Retention Program, the Company’s named executive officers and the Chief Financial Officer will receive lump sum cash retention awards in the following amounts: Richard Paulson, President and Chief Executive Officer, $1,725,000; Stuart Poulton, Executive Vice President, Chief Development Officer, $640,000; Dr. Reshma Rangwala, Executive Vice President, Chief Medical Officer and Head of Research, $725,000; and Lori Macomber, Executive Vice President, Chief Financial Officer and Treasurer, $625,000. Awards under the 2026 Leadership Cash Retention Program may be subject to repayment if the recipient’s employment is terminated for any reason other than by the Company without cause, by the participant for good reason or due to the participant’s death or permanent disability prior to the earlier of (i) 12 months from the payment date and (ii) 30 days following a qualifying corporate event. Amounts paid under the 2026 Leadership Cash Retention Program will reduce any amounts payable under previously agreed upon severance arrangements.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  KARYOPHARM THERAPEUTICS INC.
Date: July 17, 2026   By:  

/s/ Michael Mano

    Michael Mano
    Executive Vice President, Chief Legal Officer and Secretary

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents